DERM vs SKIN vs PRGO vs NVCR vs PODD

For growth investors, Insulet Corporation (PODD) is the stronger pick with 30.

7% revenue growth year-over-year, versus -29. 1% for Journey Medical Corporation (DERM). Insulet Corporation (PODD) offers the better valuation at 46. 1x trailing P/E (25. 2x forward), making it the more compelling value choice. Analysts rate Journey Medical Corporation (DERM) a "Buy" — based on 3 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On forward P/E, Perrigo Company plc is actually cheaper at 5.

6x — notably different from the trailing picture, reflecting expected earnings growth.

Over the past 5 years, Insulet Corporation (PODD) delivered a total return of -31.

5%, compared to -92. 9% for The Beauty Health Company (SKIN). Over 10 years, the gap is even starker: PODD returned +439. 0% versus SKIN's -91. 6%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Insulet Corporation (PODD) is the lower-risk stock at 0.

68β versus NovoCure Limited's 2. 20β — meaning NVCR is approximately 222% more volatile than PODD relative to the S&P 500. On balance sheet safety, Insulet Corporation (PODD) carries a lower debt/equity ratio of 69% versus 6% for The Beauty Health Company — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Insulet Corporation (PODD) is pulling ahead at 30.

7% versus -29. 1% for Journey Medical Corporation (DERM). On earnings-per-share growth, the picture is similar: The Beauty Health Company grew EPS 55. 6% year-over-year, compared to -723. 2% for Perrigo Company plc. Over a 3-year CAGR, PODD leads at 27. 5% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Insulet Corporation (PODD) is the more profitable company, earning 9.

1% net margin versus -33. 5% for Perrigo Company plc — meaning it keeps 9. 1% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: PODD leads at 17. 5% versus -24. 4% for DERM. At the gross margin level — before operating expenses — NVCR leads at 74. 5%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

On forward earnings alone, Perrigo Company plc (PRGO) trades at 5.

6x forward P/E versus 69. 0x for Journey Medical Corporation — 63. 4x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for DERM: 135. 0% to $11. 75.

In this comparison, PRGO (9.

8% yield) pays a dividend. DERM, SKIN, NVCR, PODD do not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, Insulet Corporation (PODD) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.

68), +439. 0% 10Y return). The Beauty Health Company (SKIN) carries a higher beta of 2. 00 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (PODD: +439. 0%, SKIN: -91. 6%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

These companies operate in different sectors (DERM (Healthcare) and SKIN (Consumer Defensive) and PRGO (Healthcare) and NVCR (Healthcare) and PODD (Healthcare)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.

In terms of investment character: DERM is a small-cap quality compounder stock; SKIN is a small-cap quality compounder stock; PRGO is a small-cap income-oriented stock; NVCR is a small-cap quality compounder stock; PODD is a mid-cap high-growth stock. PRGO pays a dividend while DERM, SKIN, NVCR, PODD do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.